A D V A N C I N G I N N O V A T I O N I N H E A L T H C A R E Partners Innovation Fund

Size: px

Start display at page:

Download "A D V A N C I N G I N N O V A T I O N I N H E A L T H C A R E Partners Innovation Fund"

Steven Conley
5 years ago
Views:

1 A D V A N C I N G I N N O V A T I O N I N H E A L T H C A R E Partners Innovation Fund Partners HealthCare July 2017

2 P A R T N E R S I N N O V A T I O N F U N D In Brief Capitalization $165M fund $100 million core fund capitalized by MGH and BWH $65 million strategic fund capitalized by pharma and other strategic investors Focus Medical innovations discovered and developed at Partners institutions Strategy Capital should accelerate breakthrough technologies in healthcare

P I F I N V E S T M E N T T E A M Experienced innovators, executives, entrepreneurs, and investors Deep scientific domain expertise Established track record of invention,

org Carl Berke, PhD Partner Innovator & Strategy Consultant cberke@partners.org Jay Knowles Partner BD Executive & CEO jjknowles@partners.

org 20+ years venture experience Co-Founder, Mass Medical Angels Partner, Mi3 Venture Partners Investments: CoStim, Adheron, Spero, RaNA and Magenta.

Annovation, QPID, lifeimage, Sebacia & Syntimmune FOCUS AREAS: materials, devices, diagnostics, HIT/software and chemistries 20+ years in business development CEO, X-BODY

3 P I F I N V E S T M E N T T E A M Experienced innovators, executives, entrepreneurs, and investors Deep scientific domain expertise Established track record of invention, new venture conception, and company building Proven value creation Roger Kitterman Managing Partner Entrepreneur & Venture Capitalist rkitterman@partners.org Carl Berke, PhD Partner Innovator & Strategy Consultant cberke@partners.org Jay Knowles Partner BD Executive & CEO jjknowles@partners.org Meredith Fisher, PhD Partner Life Science Investor & Scientist mcfisher1@partners.org 20+ years venture experience Co-Founder, Mass Medical Angels Partner, Mi3 Venture Partners Investments: CoStim, Adheron, Spero, RaNA and Magenta. FOCUS AREAS: therapeutics Partner, Integral/Analysis Group R&D Director, Polaroid & Hygeia Founder & Director, Mass Medical Angels Licensing Officer, MIT Investments: Annovation, QPID, lifeimage, Sebacia & Syntimmune FOCUS AREAS: materials, devices, diagnostics, HIT/software and chemistries 20+ years in business development CEO, X-BODY (acquired by Juno) BD Exec, Novartis and Vertex Investments: Abcuro, Editas, Denali, Keros, LTI, Quartet & Tilos. FOCUS AREAS: therapeutics Director, Bracebridge Capital Sr. Director of Tech & Bus Devel., PureTech Ventures/ Enlight Biosciences Scientist, Idenix & Anadys Pharma. Investments: ImmuneXcite & Lyndra. FOCUS AREAS: therapeutics and devices

E I R P R O G R A M : G R O W I N G O P E R A T I O N A L E X P E R I E N C E John Ripple CEO, Ensemble Therapeutics 20+ years biopharma experience CEO, Permeon Biologics CEO, Virdante

Early-Stage Industry Leaders Executive Leadership Operating Experience Business Development Scientific Discovery Raising Venture Capital Barbara Fox CEO, Tilos Therapeutics, Inc.

4 E I R P R O G R A M : G R O W I N G O P E R A T I O N A L E X P E R I E N C E John Ripple CEO, Ensemble Therapeutics 20+ years biopharma experience CEO, Permeon Biologics CEO, Virdante Pharmaceuticals CEO, Syntonix Pharmaceuticals BD Exec, Wyeth/Genetics Institute Advisor, MIT Deshpande Center MBA, Harvard Business School BS Mechanical Engineering, Bucknell University Experienced Early-Stage Industry Leaders Executive Leadership Operating Experience Business Development Scientific Discovery Raising Venture Capital Barbara Fox CEO, Tilos Therapeutics, Inc. 20+ years biotechnology experience CEO, Avaxia Biologics EIR, Oxford Bioscience President, Founder & CSO, Recovery Pharmaceuticals Assoc. Professor of Medicine, U of Maryland School of Medicine PhD Chemistry, MIT BA Chemistry, Bryn Mawr College

P I F I N V E S T M E N T P I P E L I N E P A R T N E R S H E A L T H C A R E S Y S T E M Pre-clinical, clinical, post-approval and observational research Longitudinal patient data: intervention,

5 P I F I N V E S T M E N T P I P E L I N E P A R T N E R S H E A L T H C A R E S Y S T E M Pre-clinical, clinical, post-approval and observational research Longitudinal patient data: intervention, cost, outcomes, patient behavior and population management Tissue and other bio-repositories Big Data and connected health P R O C E S S O F T E C H N O L O G Y I N N O V A T I O N A N D C O M P A N Y C O N C E P T I O N Annual Pipeline >10,000 Scientific Publications Annually > 500 Invention Disclosures >250 Patent Filings >50 Qualified Opportunities 3-5 NewCo Investments

P I F : A C T I V E P O R T F O L I O Name Start Sector Description Abcuro*

Therapeutics Immunotherapy platform targeting innate immune response Keros*

Extended release technology for orally administrated drugs Magenta* 2016

Immunotherapy based on repression of T regs Denali 2015 Therapeutics

therapies Quartet 2014 Therapeutics Treatments for neuropathic pain Syntimmune

Novel anti-infectives RaNA 2011 Therapeutics RNA-based therapies Sebacia 2010

6 P I F : A C T I V E P O R T F O L I O Name Start Sector Description Abcuro* 2016 Therapeutics Immuno-oncology and autoimmune therapy ImmuneXcite* 2016 Therapeutics Immunotherapy platform targeting innate immune response Keros* 2016 Therapeutics Treatment of rare muscle disorders Lyndra* 2016 Therapeutics Extended release technology for orally administrated drugs Magenta* 2016 Therapeutics Stem cell therapeutics platform Tilos* 2016 Therapeutics Immunotherapy based on repression of T regs Denali 2015 Therapeutics Neurodegenerative therapeutics LTI 2014 Therapeutics Neurodegenerative therapies Quartet 2014 Therapeutics Treatments for neuropathic pain Syntimmune 2014 Therapeutics Treatment for autoimmune disorders Spero 2013 Therapeutics Novel anti-infectives RaNA 2011 Therapeutics RNA-based therapies Sebacia 2010 Medical Devices Photoactivated topical treatment for acne lifeimage 2009 HIT Cloud based diagnostic image exchange

7 P I F H A S S T R O N G S Y N D I C A T E P A R T N E R S Established relationships with top tier venture capital and strategic industry partners $1 Billion Equity co-investment by syndicate partners in PIF portfolio companies Strategic Partners

8 P O R T F O L I O C O M P A N Y T H E R A P E U T I C A S S E T S - C L I N I C A L D E V E L O P M E N T Current Company Portfolio Company Product Late Preclinical Phase I Phase II Indication Magenta Magenta MGTA-456 Cord Blood Transplant Medicines Company Annovation ABP-700 Anesthesia Novartis CoStim PDR-001 Oncology Roche Adheron RG-6125 Rheumatoid Arthritis Syntimmune Syntimmune SYNT-001 Immunology Denali Denali RIP1 Neurodegeneration Novartis CoStim LAG-525 Oncology Novartis CoStim MBG-453 Oncology Novartis CoStim FAZ-053 Oncology Spero Spero SPR-741 Infectious Disease Keros Keros FOP LTI LTI Parkinson's Lyndra Lyndra Neuro Quartet Quartet Pain Translate (RaNA) Translate (RaNA) Cystic Fibrosis

9 L I Q U I D I T Y E V E N T S CoStim - record breaking return for an early-stage biotech company (24x if all milestones are reached) Editas Market leader in CRISPR genome editing (IPO Feb 2016) Annovation - game-changing anesthetic agent representing most significant new technology in 30 years if approved Company Description Event (Year) Acquirer / IPO Enterprise Value Novel treatments for fibrotic diseases 2015 $580M Safer Anesthesia 2015 Undisclosed Immuno-oncology drugs 2014 Undisclosed Gene Editing 2016 IPO (NASDAQ: EDIT) $639M EHR intelligence software Lysosome-based genetic disorders 2016 Undisclosed 2017 Undisclosed

10 H O W T O E N G A G E W I T H P I F HOW TO ACCESS US: Contact us directly or work through Market Sector Leader or Licensing Manager WHAT WE EXPECT: First meetings focus on science/technology, medical need and proposed development path WHAT WE DON T EXPECT: No expectation that PI will have developed business plan or an established a team/ceo OUR PROCESS: Collaborative! PIF works with scientific founder(s) to build a plan, team and investment syndicate

11 Advancing Innovation in Health Care Partners Innovation Fund Partners HealthCare 215 First Street, Suite 500 Cambridge, MA innovation.partners.org

Inaugural Fraunhofer Delaware Technology Summit

Inaugural Fraunhofer Delaware Technology Summit Energy and Life Sciences Solu